The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival.
Clinical Trial
Glioblastoma
Glioma
Neuro-oncology
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
03
06
2022
accepted:
28
06
2022
pubmed:
16
7
2022
medline:
31
8
2022
entrez:
15
7
2022
Statut:
ppublish
Résumé
To determine whether participation in a clinical trial was associated with improved survival in patients with glioblastoma (GBM). Following IRB approval, patients were identified using CPT and ICD codes. Data was collected using retrospective review of electronic medical records. When necessary, death data was obtained from online obituaries. Inverse propensity score matching was utilized to transform the two cohorts to comparable sets. Survival was compared using Kaplan-Meyer curves and Wilcoxon Rank Sum Test. In this cohort of 365 patients, 89 were enrolled in a clinical trial and 276 were not. Patients enrolled in clinical trials had a significantly higher mean baseline KPS score, higher proportion of surgical resections, and were more likely to receive temozolomide treatment than patients not enrolled in a clinical trial. After inverse propensity score matching, patients enrolled in a clinical trial lived significantly longer than those not enrolled (28.8 vs 22.2 months, p = 0.005). A potential confounder of this study is that patients not in a clinical trial had significantly fewer visits with neuro-oncologists than patients enrolled in a clinical trial (7 ± 8 vs 12 ± 9, p < 0. 0001). Clinical trials enroll patients with the most favorable prognostic features. Even when correcting for this bias, clinical trial enrollment is an independent predictor of increased survival regardless of treatment arm.
Identifiants
pubmed: 35840786
doi: 10.1007/s11060-022-04083-8
pii: 10.1007/s11060-022-04083-8
doi:
Substances chimiques
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
479-484Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol 21:v1–v100
doi: 10.1093/neuonc/noz150
Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3–8. https://doi.org/10.3171/2011.2.jns10998
doi: 10.3171/2011.2.jns10998
pubmed: 21417701
Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
doi: 10.1056/NEJMoa043330
Kamath AA, Friedman DD, Akbari SHA, Kim AH, Tao Y, Luo J, Leuthardt EC (2018) Glioblastoma treated with magnetic resonance imaging-guided laser interstitial thermal therapy: safety, efficacy, and outcomes. Neurosurgery 84:836–843. https://doi.org/10.1093/neuros/nyy375
doi: 10.1093/neuros/nyy375
pmcid: 6425465
Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu J-J, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim C-Y, Paek S-H, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316. https://doi.org/10.1001/jama.2017.18718
doi: 10.1001/jama.2017.18718
pubmed: 29260225
pmcid: 5820703
Unger JM, Cook E, Tai E, Bleyer A (2016) The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. https://doi.org/10.1200/edbk_156686
doi: 10.1200/edbk_156686
pubmed: 27249699
pmcid: 5495113
Lara PN Jr, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell L, Gonzalez J, Davis S, Umutyan A (2005) Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol 23:9282–9289
doi: 10.1200/JCO.2005.02.6245
Avis NE, Smith KW, Link CL, Hortobagyi GN, Rivera E (2006) Factors associated with participation in breast cancer treatment clinical trials. J Clin Oncol 24:1860–1867
doi: 10.1200/JCO.2005.03.8976
Unger JM, Hershman DL, Fleury ME, Vaidya R (2019) Association of patient comorbid conditions with cancer clinical trial participation. JAMA Oncol 5:326–333. https://doi.org/10.1001/jamaoncol.2018.5953
doi: 10.1001/jamaoncol.2018.5953
pubmed: 30629092
pmcid: 6439841
Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY (2020) Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro Oncol 22:601–612. https://doi.org/10.1093/neuonc/noaa015
doi: 10.1093/neuonc/noaa015
pubmed: 31974566
pmcid: 7229255
Chang SM, Barker FG, Schmidt MH, Sloan AE, Kasper R, Phillips L, Shih K, Hariharan S, Berger MS, Investigators GO (2002) Clinical trial participation among patients enrolled in the Glioma Outcomes Project. Cancer 94:2681–2687
doi: 10.1002/cncr.10536
Ludmir EB, Mandel JJ, McAleer MF, de Groot JF (2018) Disparities along the glioblastoma clinical trials landscape. Neuro Oncol 21:285–286. https://doi.org/10.1093/neuonc/noy176
doi: 10.1093/neuonc/noy176
pmcid: 6374758
Liu Y, Wasilewski A, Mohile NA (2020) Disparities in patient enrollment on glioblastoma clinical trials. CNS Oncol 9:CNS59. https://doi.org/10.2217/cns-2020-0008
doi: 10.2217/cns-2020-0008
pubmed: 32603616
pmcid: 7341158
Braunholtz DA, Edwards SJ, Lilford RJ (2001) Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect.” J Clin Epidemiol 54:217–224
doi: 10.1016/S0895-4356(00)00305-X
Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD (2008) Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev (3)
Chow CJ, Habermann EB, Abraham A, Zhu Y, Vickers SM, Rothenberger DA, Al-Refaie WB (2013) Does enrollment in cancer trials improve survival? J Am Coll Surg 216:774–780. https://doi.org/10.1016/j.jamcollsurg.2012.12.036
doi: 10.1016/j.jamcollsurg.2012.12.036
pubmed: 23415510
pmcid: 4096556
Field KM, Drummond KJ, Yilmaz M, Tacey M, Compston D, Gibbs P, Rosenthal MA (2013) Clinical trial participation and outcome for patients with glioblastoma: multivariate analysis from a comprehensive dataset. J Clin Neurosci 20:783–789
doi: 10.1016/j.jocn.2012.09.013
Shahar T, Nossek E, Steinberg DM, Rozovski U, Blumenthal DT, Bokstein F, Sitt R, Freedman S, Corn BW, Kanner AA (2012) The impact of enrollment in clinical trials on survival of patients with glioblastoma. J Clin Neurosci 19:1530–1534
doi: 10.1016/j.jocn.2012.04.005
Hart MG, Garside R, Rogers G, Stein K, Grant R (2013) Temozolomide for high grade glioma. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007415.pub2
doi: 10.1002/14651858.CD007415.pub2
pubmed: 24154977
pmcid: 6513466
Skaga E, Skretteberg MA, Johannesen TB, Brandal P, Vik-Mo EO, Helseth E, Langmoen IA (2021) Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply? Neurooncol Adv 3:vdab008. https://doi.org/10.1093/noajnl/vdab008
doi: 10.1093/noajnl/vdab008
pubmed: 33665615
pmcid: 7914075
Bagley SJ, Kothari S, Rahman R, Lee EQ, Dunn GP, Galanis E, Chang SM, Nabors LB, Ahluwalia MS, Stupp R, Mehta MP, Reardon DA, Grossman SA, Sulman EP, Sampson JH, Khagi S, Weller M, Cloughesy TF, Wen PY, Khasraw M (2021) Glioblastoma clinical trials: current landscape and opportunities for improvement. Clin Cancer Res 28:594–602. https://doi.org/10.1158/1078-0432.Ccr-21-2750
doi: 10.1158/1078-0432.Ccr-21-2750
Sedgwick P, Greenwood N (2015) Understanding the Hawthorne effect. BMJ 351:h4672. https://doi.org/10.1136/bmj.h4672
doi: 10.1136/bmj.h4672
pubmed: 26341898
McCambridge J, Witton J, Elbourne DR (2014) Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 67:267–277. https://doi.org/10.1016/j.jclinepi.2013.08.015
doi: 10.1016/j.jclinepi.2013.08.015
pubmed: 24275499
pmcid: 3969247
Lassig AA, Joseph AM, Lindgren BR, Fernandes P, Cooper S, Schotzko C, Khariwala S, Reynolds M, Yueh B (2012) The effect of treating institution on outcomes in head and neck cancer. Otolaryngol Head Neck Surg 147:1083–1092. https://doi.org/10.1177/0194599812457324
doi: 10.1177/0194599812457324
pubmed: 22875780
pmcid: 5552409
Birkmeyer JD, Sun Y, Wong SL, Stukel TA (2007) Hospital volume and late survival after cancer surgery. Ann Surg 245:777–783. https://doi.org/10.1097/01.sla.0000252402.33814.dd
doi: 10.1097/01.sla.0000252402.33814.dd
pubmed: 17457171
pmcid: 1877074